Schering AG and AstraZeneca have formed an alliance to co-develop and jointly commercialize Schering’s selective estrogen receptor downregulator (SERD). Under the terms of the agreement, the companies will develop the novel SERD with AZ leading the clinical development and Schering leading the non-clinical and process development as well as manufacturing activities. The companies will co-promote the product in the major territories. All development and commercialization costs and global pr...